tradingkey.logo

Dyadic International Inc

DYAI
1.000USD
+0.090+9.89%
收盤 12/19, 16:00美東報價延遲15分鐘
36.18M總市值
虧損本益比TTM

Dyadic International Inc

1.000
+0.090+9.89%

關於 Dyadic International Inc 公司

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.

Dyadic International Inc簡介

公司代碼DYAI
公司名稱Dyadic International Inc
上市日期Nov 05, 2004
CEOEmalfarb (Mark A)
員工數量6
證券類型Ordinary Share
年結日Nov 05
公司地址1044 North U.S. Highway One
城市JUPITER
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編33477
電話15617438333
網址https://dyadic.com/
公司代碼DYAI
上市日期Nov 05, 2004
CEOEmalfarb (Mark A)

Dyadic International Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Mark A. Emalfarb
Mr. Mark A. Emalfarb
Chief Executive Officer, Director
Chief Executive Officer, Director
4.73M
--
Ms. Ping Wang Rawson, CPA
Ms. Ping Wang Rawson, CPA
Chief Financial Officer
Chief Financial Officer
140.99K
--
Mr. Patrick K. Lucy
Mr. Patrick K. Lucy
Independent Chairman of the Board
Independent Chairman of the Board
50.76K
--
Dr. Ronen Tchelet, Ph.D.
Dr. Ronen Tchelet, Ph.D.
Vice President - Research and Business Development
Vice President - Research and Business Development
32.83K
+37.65%
Dr. Seth J. Herbst, M.D.
Dr. Seth J. Herbst, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph (Joe) Hazelton
Mr. Joseph (Joe) Hazelton
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Mark A. Emalfarb
Mr. Mark A. Emalfarb
Chief Executive Officer, Director
Chief Executive Officer, Director
4.73M
--
Ms. Ping Wang Rawson, CPA
Ms. Ping Wang Rawson, CPA
Chief Financial Officer
Chief Financial Officer
140.99K
--
Mr. Patrick K. Lucy
Mr. Patrick K. Lucy
Independent Chairman of the Board
Independent Chairman of the Board
50.76K
--
Dr. Ronen Tchelet, Ph.D.
Dr. Ronen Tchelet, Ph.D.
Vice President - Research and Business Development
Vice President - Research and Business Development
32.83K
+37.65%
Dr. Seth J. Herbst, M.D.
Dr. Seth J. Herbst, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph (Joe) Hazelton
Mr. Joseph (Joe) Hazelton
President, Chief Operating Officer
President, Chief Operating Officer
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Emalfarb (Mark A)
13.07%
Francisco Trust
9.42%
Apis Capital Advisors LLC
4.26%
Chapin Davis Asset Management
2.58%
The Vanguard Group, Inc.
2.53%
其他
68.14%
持股股東
持股股東
佔比
Emalfarb (Mark A)
13.07%
Francisco Trust
9.42%
Apis Capital Advisors LLC
4.26%
Chapin Davis Asset Management
2.58%
The Vanguard Group, Inc.
2.53%
其他
68.14%
股東類型
持股股東
佔比
Individual Investor
15.84%
Corporation
9.42%
Investment Advisor
9.03%
Hedge Fund
5.29%
Investment Advisor/Hedge Fund
1.74%
Bank and Trust
0.93%
Venture Capital
0.07%
Research Firm
0.06%
其他
57.62%

機構持股

更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
67
6.19M
14.14%
--
2025Q3
69
6.19M
14.21%
+1.17M
2025Q2
67
5.02M
17.34%
-34.61K
2025Q1
64
5.06M
17.41%
-179.68K
2024Q4
66
5.12M
16.50%
+343.55K
2024Q3
64
4.78M
17.00%
+94.58K
2024Q2
63
4.69M
16.54%
+162.98K
2024Q1
59
4.53M
16.61%
-322.18K
2023Q4
60
4.51M
16.85%
+7.33K
2023Q3
68
4.51M
17.97%
-1.09K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Emalfarb (Mark A)
4.73M
13.07%
--
--
Apr 24, 2025
Francisco Trust
3.41M
9.42%
--
--
Apr 24, 2025
Chapin Davis Asset Management
882.85K
2.44%
+40.00K
+4.75%
Jun 30, 2025
The Vanguard Group, Inc.
860.66K
2.38%
+46.32K
+5.69%
Jun 30, 2025
Truist Bank
250.00K
0.69%
--
--
Jun 30, 2025
Tarnok (Michael P)
281.03K
0.78%
+10.78K
+3.99%
Jun 20, 2025
Geode Capital Management, L.L.C.
259.15K
0.72%
+732.00
+0.28%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
249.82K
0.69%
+2.96K
+1.20%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Dyadic International Inc的前五大股東是誰?

Dyadic International Inc的前五大股東如下:
Emalfarb (Mark A)
持有股份:4.73M
佔總股份比例:13.07%。
Francisco Trust
持有股份:3.41M
佔總股份比例:9.42%。
Chapin Davis Asset Management
持有股份:882.85K
佔總股份比例:2.44%。
The Vanguard Group, Inc.
持有股份:860.66K
佔總股份比例:2.38%。
Truist Bank
持有股份:250.00K
佔總股份比例:0.69%。

Dyadic International Inc的前三大股東類型是什麼?

Dyadic International Inc 的前三大股東類型分別是:
Emalfarb (Mark A)
Francisco Trust
Apis Capital Advisors LLC

有多少機構持有Dyadic International Inc(DYAI)的股份?

截至2025Q4,共有67家機構持有Dyadic International Inc的股份,合計持有的股份價值約為6.19M,占公司總股份的14.14% 。與2025Q3相比,機構持股有所增加,增幅為-0.07%。

哪個業務部門對Dyadic International Inc的收入貢獻最大?

在--,--業務部門對Dyadic International Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI